Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma

被引:2
|
作者
Cervetti, G [1 ]
Galimberti, S [1 ]
Cecconi, N [1 ]
Caracciolo, F [1 ]
Petrini, M [1 ]
机构
[1] Univ Pisa, Dept Oncol Transplants & Adv Technol, Div Hematol, Osp S Chiara, I-56100 Pisa, Italy
关键词
Waldenstrom's macroglobulinemia; lymphoplasmocytic lymphoma; non Hodgkin's lymphoma; cladribrine;
D O I
10.1179/joc.2004.16.4.388
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cladribrine (2-CdA), a purine analogue active on both dividing and resting lymphocytes, plays an important role in the treatment of indolent lymphoproliferative malignancies such as Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Lymphoplasmocytic Lymphoma (LPL), Waldenstrom's Macroglobulinemia (WM). With the aim of evaluating the efficacy and toxicity of low dose 2-CdA, 15 lymphoplasmocytic lymphoma patients, not eligible for more aggressive or standard therapies, because of age or poor performance status, were treated with the drug at a dose of 5 mg/m(2), once a week for six total courses. All patients showed disease progression. Fourteen patients were valuable for response. In eleven out of these 14 (85.7%) disease progression stopped, with 21% having good hematological responses (one CR and two PR). The treatment was generally well tolerated, without serious infectious events. This schedule may be appropriate for the management of patients where the aim of the treatment is control of disease progression.
引用
收藏
页码:388 / 391
页数:4
相关论文
共 50 条
  • [1] Low dose 2-CdA schedule activity in Splenic Marginal Zone Lymphomas
    Riccioni, R
    Caracciolo, F
    Galimberti, S
    Cecconi, N
    Petrini, M
    HEMATOLOGICAL ONCOLOGY, 2003, 21 (04) : 163 - 168
  • [2] CLADRIBINE (2-CDA) FOR EARLY LOW-GRADE NON-HODGKINS-LYMPHOMA (LGNHL)
    LILIEMARK, J
    HAGBERG, H
    CAVALLINSTAHL, E
    JULIUSSON, G
    BLOOD, 1994, 84 (10) : A168 - A168
  • [3] 2-chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
    Schirmer, M
    Michlmayr, G
    Geisen, F
    Konwalinka, G
    LEUKEMIA, 1996, 10 (07) : 1253 - 1254
  • [4] High Activity of Cladribine (2-CdA) Combined with Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Azacitidine Failure
    Wisniewski, Kamil
    Madry, Krzysztof
    Grosicki, Sebastian
    Malecki, Piotr
    Pula, Bartosz
    Watek, Marzena
    Lech-Maranda, Ewa
    Tybor, Joanna Gora
    BLOOD, 2019, 134
  • [5] Treatment of high risk of refractory follicular-lymphocytic lymphoma with 2-CDA and High Dose Chemotherapy (HDCT) with autologous Peripheral Blood Stem Cells (PBSC)
    Martinelli, G
    Scalamogna, R
    Marrocco, E
    Ferrucci, PF
    Rabascio, C
    Mancuso, P
    Pastano, R
    Dicorato, A
    BONE MARROW TRANSPLANTATION, 2001, 27 : S273 - S274
  • [6] Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma
    Yu-Yan Hwang
    Pek-Lan Khong
    Yok-Lam Kwong
    Annals of Hematology, 2017, 96 : 1219 - 1220
  • [7] Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma
    Hwang, Yu-Yan
    Khong, Pek-Lan
    Kwong, Yok-Lam
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1219 - 1220
  • [8] Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA)
    Virchis, A
    Mehta, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (03) : 609 - 609
  • [9] The role of bryostatin 1 in 2-CdA resistant B-CLL line: Mechanism of resistance and response.
    Mohammad, RM
    Beck, FWJ
    Wall, N
    Hamdy, N
    Mendpara, SD
    Liu, KZ
    Schultz, CP
    Hannoudi, GN
    Mantsch, HH
    AlKatib, A
    BLOOD, 1997, 90 (10) : 2364 - 2364
  • [10] Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma
    Kwong, Yok-Lam
    Lopes, David
    Khong, Pek-Lan
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (01) : 131 - 132